Kidney

Mineralocorticoid receptor

Blockade

Kidney disease

Hyperlipidemia

Endocrinology

Receptor

Diabetic nephropathy

Aldosterone

Internal medicine

Pharmacology

Medicine

Endothelin receptor

Disease

Diabetes mellitus

Journal of Clinical Medicine

Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease (ESKD) in the United States. Risk factor modification, such as tight control of blood glucose, management of hypertension and hyperlipidemia, and the use of renin-angiotensin-aldosterone system (RAAS) blockade have been proven to help delay the progression of DKD. In recent years, new therapeutics including sodium-glucose transport protein 2 (SGLT2) inhibitors, endothelin antagonists, glucagon like peptide-1 (GLP-1) agonists, and mineralocorticoid receptor antagonists (MRA), have provided additional treatment options for patients with DKD. This review discusses the various treatment options available to treat patients with diabetic kidney disease.

Therapeutic Advances in Diabetic Nephropathy